Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 13, 2026CancersOpen Access

Chemotherapeutics as Immune Modulators for the Treatment of Triple-Negative Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

CFCory FinesSKSorcha KellyHMHelen O. McCarthy

Discussion

Loading...

Member takes

Overview

Review explores the role of chemotherapy in enhancing immune response in triple-negative breast cancer, suggesting new therapeutic strategies.

Key Points

  • This review aims to explore how chemotherapy affects immune cells in triple-negative breast cancer and its implications for treatment.
  • Reviewed existing literature on chemotherapy effects on immune cells in triple-negative breast cancer.
  • Discussed the role of PD-1/PD-L1 inhibitors and other immunotherapies in combination with chemotherapy.
  • Analyzed the tumor microenvironment characteristics of triple-negative breast cancer related to immune responses.
  • Chemotherapy impacts both systemic and tumor immune cells, influencing treatment effectiveness.
  • Triple-negative breast cancer exhibits an 'immune hot' microenvironment, which can be leveraged in treatment strategies.
  • Combination therapies may improve outcomes for high-risk patients by enhancing immune activity.

Cite This Study

Fines et al. (2026) studied this question.

synapsesocial.com/papers/6a0414a279e20c90b44448e9https://doi.org/10.3390/cancers18101537
View Full Paper
Ask AI
Bookmark
Share